Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$11.80B
Positions
116
New
8
Increased
21
Decreased
20
Sold Out
16
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $11.80B across 116 positions in their Q1 2018 SEC 13F filing (period ending 2018-03-31). The top 10 positions account for 80.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $2.85B | 24.18% | +0.0% |
| 2 | SGENEURSeattle Genetics, Inc. | $2.59B | 21.99% | +8.4% |
| 3 | ONCBeiGene, Ltd. | $979.34M | 8.30% | +51.4% |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | $953.64M | 8.08% | +0.0% |
| 5 | BMRNBioMarin Pharmaceutical Inc. | $614.76M | 5.21% | - |
| 6 | ACADACADIA Pharmaceuticals Inc. | $611.82M | 5.19% | - |
| 7 | GHDXGenomic Health, Inc. | $431.49M | 3.66% | +0.1% |
| 8 | ASNDUSDAscendis Pharma A/S | $185.56M | 1.57% | +8.3% |
| 9 | Aquinox Pharmaceuticals, Inc. | $153.95M | 1.30% | - |
| 10 | AveXis, Inc. | $144.24M | 1.22% | +50.6% |
| Stock | Value | Shares |
|---|---|---|
| MNLOUSDMenlo Therapeutics Inc. | $26.31M | 700,000 |
| BOLDEURAudentes Therapeutics, Inc. | $11.82M | 393,222 |
| AMRN 3.5 01/15/47Corsicanto II Designated Activity Company | $11.03M | 10,000,000 |
| GTHXEURG1 Therapeutics, Inc. | $6.28M | 169,492 |
| MNTAMomenta Pharmaceuticals, Inc. | $5.60M | 308,500 |
| SLDBSolid Biosciences Inc. | $4.41M | 587,884 |
| Solid Biosciences Inc. | $4.41M | 587,884 |
| RTTREURRitter Pharmaceuticals, Inc. | $762.00K | 279,999 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.